[Determination of acceptability of 2 cutaneous estradiol gels, in a dose of 1.5 mg daily].
OBJECTIVE
The aim was to compare acceptability of a percutaneous 0. 1% estradiol gel (Gel A, Estreva(R) Gel, Laboratoire Théramex, Monaco) to that of an 0.06% estradiol gel (Gel B, Oestrodose(R), Laboratoires Besins-Iscovesco) in its new formulation and packaging.


METHODS
This randomized, crossed, simple-blind study was carried out in 48 volunteer healthy postmenopausal women. The volunteers applied on one forearm 1.5 mg/day of cutaneous estradiol in the form of either gel, according to randomized allocation, for four days without free period between the two therapeutic periods. The application and drying times of the two gels were measured during the first application; gel subjective women assessment was collected at the beginning and at the end of the study.


RESULTS
Mean application and drying times with Gel A are significantly reduced, compared to Gel B (p=0.0259 and p=0.0001, respectively) with drying time 61% shorter; these data are confirmed by subjective women evaluation. The two gels are not significantly different regarding several criteria as consistency, ease of application and sensation of lasting stickiness. However, a significant difference is found in favour of Gel A on the following items: practicality of application (p=0.007), ease of penetration (p<0.001), quantity of gel to apply (p<0.001) after the first application. After four days of administration, a same significant difference is observed concerning practicality of the gel (p=0.0078), duration of use (p<0. 001), packaging, women opinion on the gel (p=0.022) and the product, gel and packaging (p<0.001). At the end of the study, gel A utilization is considered by women more practical (p=0.001) with an easier application (p<0.001) and less restricting while applying (p=0.001), compared to Gel B; 72.9% of women prefer the Gel A and 12. 5% of women prefer the Gel B.


CONCLUSIONS
A better acceptability of the 0.1% estradiol gel and of its packaging compared to that of the 0.06% estradiol gel in this new formulation and packaging is observed in this study.
De Lunardo
M C
MC
Laboratoire Théramex, 6, avenue Prince-Héréditaire-Albert, BP 59, 98000 Monaco.
Chevallier
T
T
Herbrecht
F
F
Micheletti
M C
MC
Parneix-Spake
A
A
Jouin
H
H
Zartarian
M
M
D000279:Administration, Cutaneous; D004958:Estradiol / Q000008:administration & dosage*; D005260:Female; D005782:Gels; D006801:Humans; D008875:Middle Aged; D017060:Patient Satisfaction; D017698:Postmenopause
D005782:Gels; D004958:Estradiol